big focu busi off-set
medtron prepar remark expect focus pipelin focu reduc outlook diabet
understand guidanc full-year revenu outlook chang divis pipelin updat net/net invest
view overw eight unchang turn long-term outlook/th pipelin
here coupl key takeaw ay read-thru full note
read-thru diabet manag reduc expect diabet grow th year much
surpris market view conjectur market given diabet leadership chang previous
announc manag expect low -singl digit grow th versu prior expect low end grow th
 off-set higher sale expect businessescardio vascular minim invas therapies/surgeri restor
therapi cite face increas competit unit state ait next gener product
note file submiss ith fda hardw data ill present aatd meet
februari algorithm ill submit data fda manag said feel good ith posit
pump side feel disadvantag cgm side
read-thru pelvic health gm call seri friday kick gener manag call seri friday ith
brook stori vice-president gener manag pelvic health gastric therapi friday et expect focu
sacral neuromodul busi given competit environ ith axon enter space face
competit year maintain overweight axn think could make continu volatil
 oo bloomberg im reach via im email call ith question kristen
 iew com pani ir present quarter click
report anoth quarter solid result ahead street expect
revenu constant currenc organ acceler
anoth quarter double-digit grow th em
op margin line ith expect
enterpris excel initi continu benefit particularli sg line ep constant currenc
overal broad-bas perform demonstr consist execut strength innov benefit diversif
rtg particularli impress perform ith organ hich ahead expect
strong grow th spine brain therapi off-set slow er sale pain therapi
surgic synergi strategi enabl capit brain implant spine except sustain impact
spine grew organ organ global exclud titan spine acquisit hich good start
organ grow th spine highest level year strong double-digit grow th infus organ spine global us
driven surgic synergi strategi particular increas use mazor lead increas implant combin spine
brain therapi capit sale hich competitor report sale organ ith us organ ell market
surgic synergi benefit brain therapi sell capit use spine brain therapi anoth good quarter ith sale
grow th neurosurgeri double-digit grow th robot navig imag mida pow ere surgic instrument grew
doubl digit launch midax system quarter
neurovascular busi high teen grow th ith strong grow th ischem hemorrhag ischem hemorrhag
strong ahead expect driven surgic innov respiratori gastrointestin renal
surgic innov grew mid-singl digit advanc stapl advanc energi advanc stapl grow th driven
new product tri stapl tri stapl reload advanc energi driven ligasur includ ligasur exact dissector
respiratori gastrointestin renal grew gi solut high singl digit driven double-digit grow th reflux care hich
includ bravo calibr free endoflip also pillcam system
cvg grew hich line ith expect
cvg gone seri -trend quarter hich manag note believ come end grow th
reflect challeng last quarter ith lvad dcb sustain headw ind ith longer-lif batteri replac
quarter chang manufactur tyrx limit suppli impact grow th high pow er
us dcb lvad teen q/q pass anniversari step dow lvad ill anniversari dcb march pacemak
crt replac implant grew first time sever year net neutral impact next year tyrx new manufactur process
launch late last month product return normal
see strong perform busi includ pace tavr combin repres revenu pace grew
mid-singl digit global high singl digit us micra leadless pacemak take share expand market regular
pacemak also take share uniqu pace featur bundl
tavr low ith mid us driven low risk indic launch evolut tavr quarter drove highest volum
final tw eek quarter
acceler cvg grow th profil back half fiscal year ith anniversari lvad improv grow th dcb improv
pacemak crt replac volum new product launch
diabet sale grew hich slightli ahead expect
us high singl digit declin anticip result competit challeng aw ait new product
ou revenu grew experienc strong consum demand intern demand drive doubl
digit grow th pump also grow th cgm consum
sean salmon take leadership diabet
emerg market revenu grew
drive strong grow th optim distribut channel
excit hat lie ahead
cvg launch evolut pro tavr valv full quarter immin pact admir av fistula indic look
expect micra av pacemak cobalt famili icds/crt linq icm outsid us also expect sever new
product eu diamond temp ablat cathet japanes valiant naviont stent graft percept quad crt-p attain activ
mitg start global launch sequenc soft tissu robot system fim use commerci sale commenc later fiscal
year fiscal year plan submit ce mark submit us approv hich hen approv allow
system placement gather data unit state
rtg mida drill platform launch pelvic health file interstim micro
pain gener spinal cord stimul hich ill display nan
diabet gener pump ill data present aatd feb earlier month announc ill put
place next-tech pathw ay program peopl ho purchas ill get hen avail
expect top-lin momentum acceler
organ grow th rate
adjust ep y/i ep ere mid-point guidanc
oper margin improv strong improv adjust sg drive improv enterpris
excel gross margin y/i reflect fx china tariff
interest expens dow driven debt issuanc tender reduc cost debt offset increas tax rate
strong prioriti y/i track nice convers target plu return min return
year continu expect organ sale grow th acceler
fx rate hold neg impact
 ith strength seen neurosurgeri neurovascular spine tavr adjust division grow th rate
cvg expect sale
mitg expect sale
ritg expect sale
diabet low singl digit organ low end reflect competit pressur hile aw ait approv
full-year margin still expect expand cc basi driven enterpris excel
non-gaap interest rate expect similar remaind year
expect grow th ith currenc neg impact impact
organ basi expect cvg diabet flat dow mitg rtg
omar mention expect either us/eu approv long list start build next year micra av
oper margin expect slight improv off-set currenc headw ind
non-gaap interest rate expect similar remaind year
ep includ headw ind current rate
look forw ard lead
strategi ork spine rtg good hand
excit futur execut pipelin focu
still earli comment specif strategi ill evolv thought focu mission ill
chang emphasi innov laser focus organ grow th rate aggress ith tuck-in capit
alloc highest grow th segment get amgr get back lead innov space confid sean
diabet busi ill get right overal expect get back share-tak mode grow amgr expect
share investor day june
cadenc growth keep mind comp influenc ell outag hurrican
differ comparison hat ill drive acceler back half pipelin ill see next year pleas
rais ep guidanc far year hile interest tax favor ill also invest support new
cadenc growth acceler grow th expect hard say hich product hit hen ill better
view hen get call februari expect acceler
tavr growth littl slow er overal market due presenc new competitor space pleas ith
grow th profil overal data aha still digest ere non-random franc heavi user edw ard
product line sure propens match seen use evolut
diabet guidanc specif chang face competit challeng hile aw ait new product launch
intern grow nice continu initi next-tech pathw ay ill defer revenu new
technolog alreadi submit area focu
outlook growth china confid china continu expect double-digit grow th differ
purchas process place around commodit product major product line separ clinic
spine busi talk robot placement result spine best seen long time result
surgic synergi strategi improv spine franchis give specif placement meaning
competit instal base gotten pretti big
cvg micra av confid approv pleas ith marvel data show aha believ data set consist ith
 hat fda ant submit fda think ill product us
sustain tavr growth still maintain expect market grow th billion calendar
track feel good period time
turn corner pain stim market market perform market come dow short
term like flattish medium mid high singl digit grow th flattish market next quarter tw think
thing done better posit space ith payer excit next-gener intelli hich ill
roll nan januari pick see trend right ay dont see get back high
singl digit hile
guidanc mitg strong quarter go extrapol back half pleas ith strength
share gain competitor stapler recal ill see continu diabet upgrad program headw ind market
share instal base increas ith europ track ith mention alreadi submit next gener hardw
pivot trial result februari
opex manag trend go forward expect deliv improv year see improv sg
year gross margin pressur driven mainli fx
tuck-in characterist would look focu innov driven grow th last year
omar compani focus grow th geoff martha ork group level look agmr look
area grow agmr
neurovascular ischem market strategi broad portfolio launch new stentriev
valu base healthcar focus econom valu system tyrx biggest exampl
good broader pictur need stakehold align alon ill take time
recoveri trial aha new ith savr versu conserv manag littl cooler use lot
invest driven incid pool versu preval pool ill continu look ork mitral replac
repair
tyrx manufactur uptak guidelin reimburs etc past quarter complet manufactur site nj
minnesota ramp began see yield ant everyth complet new process place
back normal product behind drive grow th rap-it trial help drive interest
structur heart mitral replac repair updat continu think leadership mitral valv replac
transfemor system lock dow import invest repair place prepar discuss publicli continu roll
indic tavr space bicuspid market pursu label indic restrict area
primari cell next gener mr label around time full portfolio recharg free feel good
tavr competit impact march third competitor came third quarter market share
line perhap littl low er expect trial go ould expect continu think done good job secur
us share busi sustain sort drive line ith hat expect grow th us
driven innov hen come increas procedur get clear grow th base line grow th remain pretti consist
drive grow th rate
cvg modest guid higher back half year headw ind behind ith lvad help mention ith
dcb start see sequenti grow th ith data set mow avail headw ind ith replac cycl begin
mitig crt-d biggest replac part market neutral allow see benefit new
product introduc new product famili linq ill move market import micra av hich expect
market
declin gross margin signific fx fx china tariff smaller impact gross margin rel stabl
today continu off-set ith sg improv drive margin expans
diabet go develop autom insulin system well confid get
need improv cgm think get think sensor area ork think ill area
pressur even next year ill take longer resolv
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
